TLSA — Expected Completion of Clinical Trial for Nasal Foralumab in MS
Aug 30, 2026, 4:00:00 AM UTC
Summary
Tiziana Life Sciences LTD anticipates the completion of its clinical trial for nasal foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis (NCT06890923) on August 30, 2026. The Phase II trial will evaluate the safety and potential efficacy of this treatment, focusing on immunologic response and clinical effects after six months of administration. It is currently recruiting 55 participants, and the results may have implications for treatment options in MS. More details can be found at the trial's website.
Company
TIZIANA LIFE SCIENCES LTD (TLSA)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.tizianalifesciences.comSimilar Events
Expected Completion of Clinical Trial Assessing Foralumab
TLSA is conducting a clinical trial for Foralumab, a human anti-CD3 antibody, which aims to assess its safety and efficacy in treating Alzheimer's Disease. The study, set to complete by December 1, 2026, will utilize nasal administration of Foralumab in a randomized double-blind placebo-controlled design with two treatment groups receiving different doses. Initial data suggest Foralumab may improve cognition in mouse models of Alzheimer's and it has been well-tolerated in healthy volunteers with progressive multiple sclerosis. The trial is expected to enroll 16 subjects, with screenings occurring at the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston.
Clinical Trial CompletionExpected Completion of Clinical Trial for OPN-375 Nasal Spray
Optinose US Inc. is expected to complete its clinical trial evaluating the efficacy and safety of OPN-375 nasal spray for treating adolescents with chronic rhinosinusitis without nasal polyps by October 31, 2028. The trial, identified as NCT06850805, involves 84 participants and will assess the drug's effectiveness compared to a placebo over a 12-week treatment period. OPN-375, which contains fluticasone propionate, aims to improve symptoms of chronic rhinosinusitis, including nasal congestion, facial pain, and discharge.
clinical trial completionExpected Completion of Clinical Trial for Frexalimab in Multiple Sclerosis
Sanofi's clinical trial for Frexalimab, aimed at treating adults with relapsing forms of multiple sclerosis, is expected to be completed on May 6, 2027. This Phase 3 trial is designed to measure the annualized relapse rate of Frexalimab compared to teriflunomide, recruiting 1,400 participants aged 18 to 55. Currently, the trial is in the recruiting phase since launching on December 13, 2023. The results of this trial could influence treatment options in multiple sclerosis, potentially impacting market dynamics for related therapies.
clinical trial completionExpected Completion of Clinical Trial for Toripalimab with Chemotherapy for Sinonasal Cancer
The clinical trial evaluating Toripalimab, an immunotherapy treatment, in combination with chemotherapy (Carboplatin and Docetaxel) for sinonasal cancers is expected to complete on February 1, 2029. The study, based at the Dana-Farber Cancer Institute and sponsored by Glenn J. Hanna, aims to assess the safety and efficacy of this regimen prior to surgery. Although Toripalimab has FDA approval for nasopharyngeal carcinoma, it is not yet approved for sinonasal cancers. The trial plans to enroll approximately 20 participants, with procedures including screening and various imaging tests. Coherus Biosciences is funding the study.
Expected Clinical Trial Completion Date